The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

A new antibody shot could help infants who contract respiratory ... significant lasting difference in what RSV, how it impacts our community." The treatment is also recommended for older adults ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

RSV is a major respiratory pathogen, particularly among young children, causing severe lower ... ribavirin—an antiviral previously used for RSV treatment—showed minimal efficacy.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Many people recover quickly, but RSV can lead to more severe respiratory illness in infants, young children, and adults over the age of 65 years. RSV is a leading cause of pneumonia and bronchitis ...